These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15682170)

  • 1. Introduction to graft-versus-host disease.
    Ringdén O
    Biol Blood Marrow Transplant; 2005 Feb; 11(2 Suppl 2):17-20. PubMed ID: 15682170
    [No Abstract]   [Full Text] [Related]  

  • 2. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
    Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira MY
    Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current status and issues in hematopoietic stem cell transplantation].
    Harada M
    Fukuoka Igaku Zasshi; 2007 Feb; 98(2):35-47. PubMed ID: 17396570
    [No Abstract]   [Full Text] [Related]  

  • 4. Graft vs. host disease: pathology, prophylaxis and therapy: GVHD overview.
    Weisdorf D
    Best Pract Res Clin Haematol; 2008 Jun; 21(2):99-100. PubMed ID: 18503978
    [No Abstract]   [Full Text] [Related]  

  • 5. Prophylaxis and management of graft-versus-host disease.
    Ezzone S
    Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):45. PubMed ID: 19856580
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunity and transplantation.
    Navarrete CV
    Vox Sang; 2004 Jul; 87 Suppl1():39-42. PubMed ID: 15200602
    [No Abstract]   [Full Text] [Related]  

  • 7. Protecting the host naturally.
    Sykes M; Spitzer TR
    Nat Med; 2005 Nov; 11(11):1164-5. PubMed ID: 16270073
    [No Abstract]   [Full Text] [Related]  

  • 8. [Reevaluation of mechanisms of GVHD and GVL].
    Teshima T
    Rinsho Ketsueki; 2008 Aug; 49(8):592-7. PubMed ID: 18800607
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy by allogeneic stem cell transplantation.
    Ringdén O
    Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome.
    Skert C; Patriarca F; Sperotto A; Cerno M; Filì C; Zaja F; Stocchi R; Geromin A; Damiani D; Fanin R
    Haematologica; 2006 Feb; 91(2):258-61. PubMed ID: 16461315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Graft-versus-host disease: friend or foe?].
    Kanda Y
    Rinsho Ketsueki; 2008 Aug; 49(8):583-91. PubMed ID: 18800606
    [No Abstract]   [Full Text] [Related]  

  • 12. Chronic graft-versus-host disease: how can we release Prometheus?
    Teshima T; Wynn TA; Soiffer RJ; Matsuoka K; Martin PJ
    Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):142-50. PubMed ID: 18162235
    [No Abstract]   [Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.
    Lee S; Cho BS; Kim SY; Choi SM; Lee DG; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Shin WS; Kim CC
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1083-94. PubMed ID: 17697971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated acral dermatitis due to graft-versus-host disease.
    van der Velden W; Lesterhuis J; Blokx W; Schattenberg A
    Eur J Haematol; 2009 Apr; 82(4):326. PubMed ID: 19077047
    [No Abstract]   [Full Text] [Related]  

  • 16. Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.
    Bridge AT; Nelson RP; Schwartz JE; Mirowski GW; Billings SD
    Am J Dermatopathol; 2007 Feb; 29(1):1-6. PubMed ID: 17284954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus-containing graft-versus-host disease prophylaxis in patients with lymphoma.
    Mehta J
    J Clin Oncol; 2009 Oct; 27(28):e138; author reply e139-40. PubMed ID: 19720890
    [No Abstract]   [Full Text] [Related]  

  • 18. Graft-versus-host disease: case report and review of literature.
    Jing X; Halat S; Meleg-Smith S
    J La State Med Soc; 2006; 158(1):20-4. PubMed ID: 16602481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation.
    Saito TI; Rubio MT; Sykes M
    Exp Hematol; 2006 Sep; 34(9):1271-7. PubMed ID: 16939820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
    Creamer D; Martyn-Simmons CL; Osborne G; Kenyon M; Salisbury JR; Devereux S; Pagliuca A; Ho AY; Mufti GJ; du Vivier AW
    Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.